News

ESCRS 2026 real-world data: aceclidine (VIZZ; LENZ Therapeutics) drops show fast onset, high satisfaction for presbyopia.

Three-year ESCRS 2026 data show trans-epithelial PRK matches conventional PRK in refractive outcomes, safety, and pain, with faster surgical time.

A real-world study of an enhanced monofocal IOL found most patients achieved 20/20 distance vision and functional intermediate vision without glasses, according to Jai Parekh, MD, MA, FAAO, at ESCRS 2026.

New ESCRS 2026 data show corneal measurements shift meaningfully across the day, with early-morning readings potentially biased by overnight eyelid closure.

At ESCRS 2026 in London, Radhika Rampat, MBBS, FRCOphth, describes bringing low-level light therapy into her refractive practice, from dry eye care to chalazion treatment and pre-surgical ocular surface optimisation.

Suzana Konjevoda, MD, presents data at ESCRS 2026 showing citicoline eye drops aid corneal nerve recovery post-cataract surgery.

ESCRS 2026 study shows multifocal IOLs tie at distance, but reading speed plunges in dim light; focus curves predict laser touch-ups.

Mingo-Botín, MD, PhD, discusses ESCRS 2026 data on an EDOF IOL in post-LASIK eyes vs non-LASIK controls.

Real-world data show tear film and Schirmer improvements with two preservative-free dry eye drops at ESCRS 2026.

Suzana Konjevoda, MD, previews ESCRS 2026, highlighting new IOLs, presbyopia correction, AI in everyday practice, and advances in post-cataract surgery recovery and comfort.

Handheld IC1000 pairs rebound tonometry with camera-guided alignment

Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.

Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.

New research covers a 3D OCT foundation model, an OCTA biomarker review and offline smartphone screening for three retinal diseases.

A gamified program may speed the brain’s adjustment, new data suggest.

Thyroid Eye Disease (TED) is an autoimmune condition affecting around one in 1,000 people in Europe. Its variability of symptoms and close association with Graves' disease, a separate thyroid disorder, can lead to considerable challenges in diagnosis. Earlier detection depends on strong collaboration between endocrinologists and ophthalmologists, as well as conversations that fully explore the impact of symptoms on patients' daily lives.

Sponsored by Bayer

João Pedro Marques, MD, PhD, on how systematic reanalysis moved a cohort's solved rate from 59.4% to 70.1% and what it means for gene therapy eligibility

A systematic review of 21 studies found OCTA detects early diabetic retinopathy—reduced vessel density being the most consistent biomarker—but heterogeneous, unstandardized evidence isn't sufficient for routine clinical screening yet.

Japan designated gildeuretinol an orphan drug for Stargardt disease as the oral therapy enters phase 3 evaluation in the NORTHSTAR trial.

A preclinical study of the effects of aflibercept (Eylea, Regeneron Pharmaceuticals) and faricimab (Vabysmo-svoa, Genentech) showed that the two treatments were equal in their ability to maintain or restore the retinal endothelial barrier function and resultant visual integrity. Investigators attributed this result mainly to inhibiting vascular endothelial growth factor A165 from binding to its receptor.

Matias Iglicki, MD, PhD, on patient selection, technical pitfalls and why symmetry decides outcomes in flanged vs sutured fixation

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

AI model beats human graders at spotting glaucoma risk in UK population retinal photos, boosting accuracy and strengthening the case for scalable AI vision screening.

A maternal high-fat diet can negatively affect the retinal structure in mice.

Real-world insights into Artelac Complete, a preservative-free, multi-component tear substitute

In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.